Defeating migraine pain with triptans: A race against the development of cutaneous allodynia

Many migraine patients find triptan therapy helpful for pain relief. However, some do not experience relief. This study investigates how cutaneous allodynia affects triptan therapy success. Cutaneous allodynia develops gradually in over 70% of migraine patients. Researchers studied 31 patients during three clinic visits: baseline, first hour, and four hours into an attack. They measured pain thresholds to mechanical and thermal stimulation on the skin. In 34 attacks with allodynia, only 15% became pain-free after triptan treatment. In contrast, 93% of nonallodynic attacks achieved pain relief. Timing of treatment did not change effectiveness for allodynic patients. However, early treatment before allodynia significantly improved pain relief success. Patients not experiencing allodynia were likely to achieve pain-free status anytime after pain onset. The study shows that timing triptan therapy before allodynia increases the chances of pain relief. Clinical relevance: This research highlights the importance of timely triptan therapy to enhance migraine pain relief.